Takeda Pharmaceutical Company Limited - ADR earnings per share and revenue
On Jan 28, 2026, TAK reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of 46.75 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 1.20 trillion, with a --% difference.
Looking ahead to Q4 26, 5 analysts forecast an EPS of -20.71 USD, with revenue projected to reach 1.10 trillion USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Takeda Pharmaceutical Company Limited - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Takeda Pharmaceutical Company Limited - ADR reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Takeda Pharmaceutical Company Limited - ADR's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Takeda Pharmaceutical Company Limited - ADR expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Takeda Pharmaceutical Company Limited - ADR's next earnings report?
Based on 5
analysts, Takeda Pharmaceutical Company Limited - ADR is expected to report EPS of -$20.71 and revenue of $1.10T for Q4 2026.